A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors

被引：0
|
作者：
Yu, X. [1 ]
Zhang, J. [2 ]
Liu, R. [2 ]
Deng, Y. [3 ]
Cai, Y. [3 ]
Sun, Y. [4 ]
Dang, Q. [4 ]
Hong, W. [5 ]
Song, Z. [6 ]
Guo, S. [2 ,7 ]
Gao, S.
Su, W. [8 ]
Shi, M. [8 ]
Fan, S. [8 ]
Zhang, B. [8 ]
Pan, B. [8 ]
Ren, Y. [8 ]
Wang, J. [8 ]
Zhong, C. [8 ]
Ma, L. [8 ]
机构：
[1] Fudan Univ, Dept Pancreat Surg, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China
[4] Shandong Canc Hosp & Inst, Phase Clin Study Ctr 1, Jinan, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Dept Thorac Med Oncol, Canc Hosp, Hangzhou, Peoples R China
[6] Univ Chinese Acad Sci, Canc Hosp, Phase Clin Study Ward 1, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Henan Univ Sci & Technol, Dept Med Oncol, Affiliated Hosp 1, Luoyang, Peoples R China
[8] HUTCHMED China Ltd, R&D, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77MO
引用
收藏
页码：S1496 / S1497
页数：2
相关论文
共 50 条
  • [41] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Johanna C. Bendell
    David S. Hong
    Howard A. Burris
    Aung Naing
    Suzanne F. Jones
    Gerald Falchook
    Patricia Bricmont
    Agnes Elekes
    Edwin P. Rock
    Razelle Kurzrock
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 125 - 130
  • [42] A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Schram, A. M.
    Boni, V.
    Adjei, A. A.
    Olszanski, A. J.
    Vieito, M.
    Francis, J. H.
    Kurman, M.
    Ahsan, J. M.
    Tomkinson, B.
    Garralda, E.
    ESMO OPEN, 2025, 10 (03)
  • [43] A PHASE 1, FIRST IN HUMAN, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF TST005 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
    Chen, Lei
    Tolcher, Anthony
    Gabrail, Nashat
    Barve, Minal
    Wu, Xiaohua
    Zhang, Jian
    Shi, Michael
    Qi, Chuan
    Yu, Steven
    Yao, Jenny
    Wang, Jianming
    Cavanaugh, Christopher
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A802 - A802
  • [44] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
    Lakhani, Nehal J.
    Chow, Laura Q. M.
    Gainor, Justin F.
    LoRusso, Patricia
    Lee, Keun-Wook
    Chung, Hyun Cheol
    Lee, Jeeyun
    Bang, Yung-Jue
    Hodi, Frank Stephen
    Kim, Won Seog
    Santana-Davila, Rafael
    Fanning, Philip
    Squifflet, Pierre
    Jin, Feng
    Kuo, Tracy C.
    Wan, Hong, I
    Pons, Jaume
    Randolph, Sophia S.
    Messersmith, Wells A.
    LANCET ONCOLOGY, 2021, 22 (12): : 1740 - 1751
  • [45] A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors.
    Papadopoulos, Kyriakos P.
    Jonasch, Eric
    Zojwalla, Naseem J.
    Wang, Keshi
    Bauer, Todd Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Olszanski, Anthony J.
    Desai, Madhuri
    Jansen, Mendel
    Scheyer, Richard David
    Senaldi, Giorgio
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours
    Powderly, J.
    Bendell, J. C.
    Carneiro, B. A.
    Italiano, A.
    Macarulla Mercade, T.
    Castanon Alvarez, E.
    Imbimbo, M.
    Massard, C.
    Mueller, N.
    Gasco-Hernandez, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S728 - S729
  • [48] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
    Ribrag, Vincent
    Iglesias, Lara
    De Braud, Filippo
    Ma, Brigette
    Yokota, Tomoya
    Zander, Thomas
    Spreafico, Anna
    Subbiah, Vivek
    Illert, Anna L.
    Tan, Daniel
    Santoro, Armando
    Munster, Pamela N.
    Suehiro, Youko
    Wang, Yongsheng
    Ji, Dong-Mei
    Chen, Shuqi
    Beltz, Karen
    Suenaga, Naoko
    Ramkumar, Thiruvamoor
    Luo, Fangjun
    Lai, Clinton
    Wainberg, Zev A.
    EUROPEAN JOURNAL OF CANCER, 2025, 216
  • [50] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
12345